Skip to main content

Ali Rizvi, M.D.

Practicing Location
Languages Spoken
  • English
  • Hindi
  • Punjabi
  • Urdu


Dr. Rizvi’s practice focuses on diabetes, metabolic syndrome, thyroid disorders, and general endocrinology problems, with a particular interest in the optimal management of diabetes (type 1 and type 2) and its complications.


Dr. Rizvi received his M.D. degree from the King Edward Medical College in Pakistan. He completed his residency in Internal Medicine at the Cleveland Clinic and a fellowship in Endocrinology, Diabetes and Metabolism at Stanford University.


Dr. Rizvi has held academic positions at the Medical College of Georgia, University of South Carolina, and Emory University. He has had extensive experience in treating patients with endocrine and metabolic disorders and teaching endocrinology fellows, internal medicine residents, and medical students. Dr. Rizvi has received several research grants, authored 150- plus peer-reviewed publications, and volunteers extensively in the community.

Caring for his patients and training future doctors give him the greatest satisfaction. “I am excited to join the UCF College of Medicine because I can align my work philosophy with the UCF goals of excellence and compassionate patient care, teaching and mentoring of future doctors, contributing to medical research and scholarship, and giving back to the community through service and volunteering,” he said.  “I strive to keep my patients’ best interests as my highest priority.”

Peer Reviewed

  • Rizvi AA. Metabolic Aspects of Five Commonly Used Non-Insulin Anti-Hyperglycemic Medications in Type 2 Diabetes. Journal of Modern Medicinal Chemistry, 2021;9:25-31.
  • Rizvi AA, Stoian AP, Rizzo M. Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies. Int J Mol Sci. 2021 Sep 17;22(18):10038.
  • Popovic DS, Papanas N, Pantea Stoian A, Rizvi AA, Janez A, Rizzo M. Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review. Diabetes Ther. 2021 Dec;12(12):3037-3054.
  • Ceriello A, Rizvi AA, Rizzo M. Glycemic Variability, Glycated Hemoglobin, and Cardiovascular Complications: Still a Dilemma in Clinical Practice. Adv Ther. 2021 Nov 10.
  • Rizvi AA, Stoian AP, Janez A, Rizzo M. Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options. Biomedicines. 2021 Oct 29;9(11):1579.
  • Rizvi AA, Janez A, Rizzo M. Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues. Int J Mol Sci. 2021 Nov 15;22(22):12311. doi: 10.3390/ijms222212311. PMID: 34830193.
  • Al Mahmeed W, Al-Rasadi K, Banerjee Y, Ceriello A, Cosentino F, Galia M, Goh SY, Kempler P, Lessan N, Papanas N, Rizvi AA, Santos RD, Stoian AP, Toth PP, Rizzo M; CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO). Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. Front Cardiovasc Med. 2021 Dec 15;8:787761.
  • Stoian AP, Kempler P, Stulnig T, Rizvi AA, Rizzo M. Diabetes and COVID-19: What 2 Years of the Pandemic Has Taught Us. Metab Syndr Relat Disord. 2021 Dec 30.
  • Nikolic D, Patti AM, Giglio RV, Chianetta R, Castellino G, Magán-Fernández A, Citarrella R, Papanas N, Janez A, Stoian AP, Rizvi AA, Rizzo M. Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study. Diabetes Ther. 2022 Feb 15.
  • Rizvi AA, Linhart A, Vrablik M, Liberopoulos E, Rizzo M. Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert Opin Drug Saf. 2022 Feb 21.